Over the last few years, significant progress has been made in the field of targeted therapies for some breast cancer subtypes, such as endocrine therapy for hormone-receptor-positive tumors or trastuzumab for tumors with HER2 overexpression. Here, ERBB2 is linked to breast cancer.